Letter: predicting azathioprine-associated pancreatitis in IBD-phenotype or genotype? Authors' reply
Aliment Pharmacol Ther
.
2018 Apr;47(7):1044-1045.
doi: 10.1111/apt.14562.
Authors
A Wilson
1
2
3
,
L E Jansen
4
,
R V Rose
5
,
J C Gregor
2
,
T Ponich
2
,
N Chande
2
,
R Khanna
2
,
B Yan
2
,
V Jairath
2
5
,
N Khanna
2
,
M Sey
2
,
M Beaton
2
,
K McIntosh
2
,
W A Teft
1
,
R B Kim
1
Affiliations
1
Division of Clinical Pharmacology, Department of Medicine, Western University, London, ON, Canada.
2
Division of Gastroenterology, Department of Medicine, Western University, London, ON, Canada.
3
Department of Physiology & Pharmacology, Western University, London, ON, Canada.
4
London Health Sciences Centre, London, ON, Canada.
5
Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.
PMID:
29512906
DOI:
10.1111/apt.14562
No abstract available
Publication types
Letter
Comment
MeSH terms
Azathioprine
Genotype
Humans
Inflammatory Bowel Diseases*
Pancreatitis*
Phenotype
Substances
Azathioprine